StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about AIFF. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $1.81 | $1.78 | -1.66% | 0.4M |
| 05-15 | $1.71 | $1.70 | -0.58% | 0.3M |
| 05-18 | $1.68 | $1.66 | -1.19% | 0.2M |
| 05-19 | $1.65 | $1.66 | +0.61% | 0.1M |
| 05-20 | $1.64 | $1.68 | +2.44% | 0.3M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Firefly Neuroscience Inc is an artificial intelligence company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. The firm is developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The company has one reportable segment: the BNA platform. The Company derives revenue from North America.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $485.00K | $1.14M | $730.00K | $342.00K |
Operating Income | $-2.01M | $-8.86M | $-6.36M | $-3.70M |
Net Income | $-2.00M | $-19.88M | $-17.40M | $-1.83M |
EPS (Diluted) | $-0.13 | $-1.97 | $-1.81 | $-1.69 |
Total Assets | $10.91M | $10.48M | $12.41M | $14.94M |
Total Liabilities | $2.47M | $2.84M | $2.75M | $2.84M |
Cash & Equivalents | $3.13M | $2.75M | $4.33M | $5.92M |
Free Cash Flow OCF − CapEx | $-2.01M | $-8.32M | $-6.49M | $-4.92M |
Shares Outstanding | 14.87M | 13.96M | 13.48M | 13.30M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.